[go: up one dir, main page]

WO2005003335A3 - Rapamycin resistant t cells and therapeutic uses thereof - Google Patents

Rapamycin resistant t cells and therapeutic uses thereof Download PDF

Info

Publication number
WO2005003335A3
WO2005003335A3 PCT/US2004/018609 US2004018609W WO2005003335A3 WO 2005003335 A3 WO2005003335 A3 WO 2005003335A3 US 2004018609 W US2004018609 W US 2004018609W WO 2005003335 A3 WO2005003335 A3 WO 2005003335A3
Authority
WO
WIPO (PCT)
Prior art keywords
rapamycin
cells
functions
treatment
addition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/018609
Other languages
French (fr)
Other versions
WO2005003335A9 (en
WO2005003335A2 (en
Inventor
Daniel H Fowler
Unsu Jung
Ronald E Gress
Bruce Levine
Carl June
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
US Department of Health and Human Services
Original Assignee
University of Pennsylvania Penn
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn, US Department of Health and Human Services filed Critical University of Pennsylvania Penn
Priority to CA2529244A priority Critical patent/CA2529244C/en
Publication of WO2005003335A2 publication Critical patent/WO2005003335A2/en
Publication of WO2005003335A3 publication Critical patent/WO2005003335A3/en
Publication of WO2005003335A9 publication Critical patent/WO2005003335A9/en
Priority to US11/298,313 priority patent/US7718196B2/en
Anticipated expiration legal-status Critical
Priority to US12/750,374 priority patent/US8075921B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Methods for generating highly enriched Thl/Tcl and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.
PCT/US2004/018609 2001-07-02 2004-06-10 Rapamycin resistant t cells and therapeutic uses thereof Ceased WO2005003335A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2529244A CA2529244C (en) 2003-06-12 2004-06-10 Rapamycin resistant t cells and therapeutic uses thereof
US11/298,313 US7718196B2 (en) 2001-07-02 2005-12-09 Rapamycin-resistant T cells and therapeutic uses thereof
US12/750,374 US8075921B2 (en) 2001-07-02 2010-03-30 Rapamycin-resistant T cells and therapeutic uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47873603P 2003-06-12 2003-06-12
US60/478,736 2003-06-12

Related Parent Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2002/020415 Continuation-In-Part WO2003004625A1 (en) 2001-07-02 2002-06-26 Methods of generating human cd4+ th2 cells and uses thereof
US10/481,913 Continuation-In-Part US20040175827A1 (en) 2001-07-02 2002-06-26 Methods of generating human cd4+ th2 cells and uses thereof
US10481913 Continuation-In-Part 2002-06-26
US11/298,313 Continuation-In-Part US7718196B2 (en) 2001-07-02 2005-12-09 Rapamycin-resistant T cells and therapeutic uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/298,313 Continuation-In-Part US7718196B2 (en) 2001-07-02 2005-12-09 Rapamycin-resistant T cells and therapeutic uses thereof

Publications (3)

Publication Number Publication Date
WO2005003335A2 WO2005003335A2 (en) 2005-01-13
WO2005003335A3 true WO2005003335A3 (en) 2005-06-09
WO2005003335A9 WO2005003335A9 (en) 2005-09-29

Family

ID=33563779

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/018609 Ceased WO2005003335A2 (en) 2001-07-02 2004-06-10 Rapamycin resistant t cells and therapeutic uses thereof

Country Status (2)

Country Link
CA (1) CA2529244C (en)
WO (1) WO2005003335A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0503936D0 (en) * 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound
GB0603081D0 (en) 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
WO2010083298A1 (en) * 2009-01-14 2010-07-22 Health Research Inc. Methods and compositions containing mtor inhibitors for enhancing immune responses
CN111454903B (en) * 2020-05-06 2023-10-20 青岛瑞思德生物科技有限公司 Immune cell in vitro culture, induction, activation and cryopreservation method and cell bank establishment thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004625A1 (en) * 2001-07-02 2003-01-16 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Methods of generating human cd4+ th2 cells and uses thereof
WO2003038062A2 (en) * 2001-10-31 2003-05-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Generation of use of tc1 and tc2 cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004625A1 (en) * 2001-07-02 2003-01-16 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Methods of generating human cd4+ th2 cells and uses thereof
WO2003038062A2 (en) * 2001-10-31 2003-05-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Generation of use of tc1 and tc2 cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FOWLER D H ET AL: "CD8+ T cells of Tc2 phenotype mediate a GVL effect and prevent marrow rejection", VOX SANGUINIS, S. KARGER AG, BASEL, CH, vol. 74, no. SUPPL 2, 1998, pages 331 - 340, XP002964509, ISSN: 0042-9007 *
FOWLER D H ET AL: "Th2 and Tc2 cells in the regulation of GVHD, GVL and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma", LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, vol. 38, 2000, pages 221 - 234, XP002964507, ISSN: 1042-8194 *
FOWLER D-H ET AL: "Allospecific CD8+ Tcl and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 157, no. 11, 1996, pages 4811 - 4821, XP002964512, ISSN: 0022-1767 *
KOGAN YELENA L ET AL: "Ex vivo Rapamycin for GVHD prevention via Th2 cell graft engineering.", BLOOD, vol. 102, no. 11, 16 November 2003 (2003-11-16), & 45TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 06-09, 2003, pages 238a, XP008043140, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2005003335A9 (en) 2005-09-29
CA2529244A1 (en) 2005-01-13
CA2529244C (en) 2014-02-18
WO2005003335A2 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
GEP20053658B (en) Soluble CTLA4 Mutant Molecules and Uses Thereof
FI3578201T3 (en) METHODS AND COMPOSITIONS FOR NATURAL KILLER CELLS
WO2005000245A3 (en) Compositions and methods for increasing telomerase activity
AU2003292137A1 (en) Rapamycin and il-10 for the treatment of immune diseases
IL172700A (en) Methods of producing cross-reactive and neutralizing anti-kir2dl antibodies and medicaments comprising the same for use in evaluating the toxicity of the antibodies
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2002028904A3 (en) Human anti-cd40 antibodies
WO2003025149A3 (en) Cell populations which co-express cd49c and cd90
WO2018005521A3 (en) Cell culture chambers and methods of use thereof
AU6649996A (en) Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
WO2004050096A3 (en) Phosphoantigens for regulating an immune response
WO2023288338A3 (en) Polycistronic vectors for cell-based therapies
WO2005115447A3 (en) Human anti-cancer immunotherapy
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
WO2005003335A3 (en) Rapamycin resistant t cells and therapeutic uses thereof
WO2007120170A3 (en) Compositions and methods for treating gram positive bacterial infection in a mammalian subject
TW200642682A (en) A combination of medical drugs to augment the anti-cancer effect of chemotherapy
WO2005017160A3 (en) Mobilization of hematopoietic cells
WO2004012652A3 (en) Treatment of multiple sclerosis with brain targeted anti oxidant compounds
WO2003007900A3 (en) Skin treatment
WO2000057908A3 (en) Attenuated dengue-1 virus vaccine
WO2000057904A3 (en) Attenuated dengue-3 virus vaccine
PL1699468T3 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/31-31/31, DRAWINGS, REPLACED BY NEW PAGES 1/31-31/31; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2529244

Country of ref document: CA

122 Ep: pct application non-entry in european phase